Reducing the global burden of HTLV-1 infection: An agenda for research and action

Luc Willems, Hideki Hasegawa, Roberto Accolla, Charles Bangham, Ali Bazarbachi, Umberto Bertazzoni, Anna Barbara de Freitas Carneiro-Proietti, Hua Cheng, Luigi Chieco-Bianchi, Vincenzo Ciminale, Jordana Coelho-dos-Reis, José Esparza, Robert C. Gallo, Antoine Gessain, Eduardo Gotuzzo, William Hall, Joseph Harford, Olivier Hermine, Steven Jacobson, Beatrice MacchiCalum Macpherson, Renaud Mahieux, Masao Matsuoka, Edward Murphy, Jean Marie Peloponese, Viviana Simon, Yutaka Tagaya, Graham P. Taylor, Toshiki Watanabe, Yoshihisa Yamano

Research output: Contribution to journalReview articlepeer-review

102 Scopus citations


Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalAntiviral Research
StatePublished - 1 Jan 2017


  • HTLV-1
  • Leukemia
  • Oncogene
  • Retrovirus
  • Vaccine


Dive into the research topics of 'Reducing the global burden of HTLV-1 infection: An agenda for research and action'. Together they form a unique fingerprint.

Cite this